The Effect of Ferric Carboxymaltose on Fibroblast Growth Factor 23 (FGF23) in Children with Iron Deficiency Anemia Due to Gastrointestinal Diseases

<b>Background:</b> Hypophosphatemia is a known side-effect of parenteral iron administration, especially after intravenous ferric carboxymaltose (FCM). Fibroblast growth factor 23 (FGF23) is thought to play an important role in the pathophysiology of serum phosphate homeostasis. This study aimed to...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Maria Ntoumpara, Elpis Mantadakis, Lemonia Skoura, Paraskevi Panagopoulou, Elpida Emmanouilidou-Fotoulaki, Eleftheria Parasidou, Paraskevoula Koutra, Maria Fotoulaki
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-11-01
coleção:	Hemato
Assuntos:	iron deficiency iron deficiency anemia parenteral iron ferric carboxymaltose fibrobast growth factor 23 hypophosphatemia
Acesso em linha:	https://www.mdpi.com/2673-6357/5/4/34
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!